ArticleExploration of targeted anti-tumor therapy2026
Lorlatinib in advanced ALK-positive NSCLC after prior progression on ALK inhibitors: real-world experience in Russia.
Sergey V Orlov et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.